Cell and Gene Therapy · global
Off-the-Shelf CAR-T Moves Toward Autoimmune Diseases: Early zugo-cel Trial Shows Improvements in Scleroderma and Myositis
Can a cell therapy that does not require individual manufacturing for each patient ease the burden of refractory autoimmune diseases? Zugo-cel has shown signs of efficacy in a small Phase 1 trial, but more complete evidence is needed to determine how long responses last and what risks treatment carries.
For patients with autoimmune diseases that respond poorly to existing treatments, long-term suppression of the immune system may not stop disease from continuing to erode daily life. CRISPR Therapeutics announced on November 8 that its off-the-shelf CAR-T therapy, zugocabtagene geleucel (zugo-cel), led to improvements in some patients with systemic sclerosis and myositis in a Phase 1 trial. This offers new clues for the use of cell therapy in autoimmune diseases, although the evidence still comes from a small number of participants.
Zugo-cel, formerly known as CTX112, is an allogeneic CAR-T therapy edited using CRISPR/Cas9 that targets CD19 on the surface of B cells. It uses donor cells and is designed to be prepared in advance without requiring human leukocyte antigen (HLA) matching; patients must still receive drugs to reduce their lymphocyte counts before infusion. Thus, “off-the-shelf” may simplify cell supply, but it does not mean the treatment process has become straightforward.
The scleroderma data presented at the American College of Rheumatology annual meeting covered seven patients as of July 21 who had received 100 million CAR-positive cells and had at least three months of follow-up. Six received a standard lymphodepletion regimen; five met the composite response measure rCRISS-25 at month three, and two met the more stringent rCRISS-50. The company said all five responders maintained their responses, with four followed for at least six months; these improvements in scores do not yet equate to a cure.
The later update to the overall data, as of October 15, included 21 treated patients: eight with scleroderma, nine with idiopathic inflammatory myopathies, and four with systemic lupus erythematosus. All nine patients with myopathies achieved moderate or major improvement on the Total Improvement Score (TIS). Myopathies and scleroderma are assessed using different tools, so these results should be interpreted separately and cannot be combined into a single efficacy rate.
On safety, the company said no cytokine release syndrome above Grade 2 had been reported among the 21 patients, nor had any immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease, or deaths been reported. However, small trials are less able to detect rare or delayed problems; current observations are not sufficient to establish long-term safety.
Background Context
CAR-T applications are expanding from cancer to autoimmune diseases, with treatment goals also shifting toward eliminating B cells that may be involved in abnormal immune responses. If allogeneic manufacturing can deliver both efficacy and supply, it could reduce the wait and burden associated with manufacturing for each individual patient. However, this announcement did not provide comparisons of costs or practical access, so it cannot establish how much the therapy might lower barriers to treatment.
These results were primarily released by the developer, with small numbers in each disease group and different data cutoff dates. The announcement did not provide controlled evidence sufficient for comparison with current therapies. The next questions are whether improvements in scores translate into lasting benefits in organ function and quality of life, and whether patients can remain stable after reducing immunosuppressive treatment. For a therapy still undergoing dose exploration, early responses are a starting point; long-term follow-up will gradually define its clinical role.